Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Eisai licenses Fragmin from Pfizer
Eisai also will assume responsibility for post-marketing studies and product distribution, as well as book all US sales. According to this agreement, Pfizer will transfer the new drug
Eisai also will assume responsibility for post-marketing studies and product distribution, as well as book all US sales. According to this agreement, Pfizer will transfer the new drug
In the study the stem cells differentiated into cells displaying the characteristics of nucleus pulposus that forms the soft gel-like center of an intervertebral disc that is adversely
This drug candidate, SB-743921, is being developed under an alliance focused on novel small molecule therapeutics targeting human mitotic kinesins for applications in the treatment of cancer and
BIVN-401 was given to 25 patients with genotype 4 hepatitis C who had failed a prior treatment. The drug was given orally for 100 days and measurement of
Medicago will receive milestone payments from Acambis to assess the feasibility of using Medicago’s Proficia protein technology for the production of vaccines. “We believe that our Proficia technology
Researchers used neurotensin receptor knock-out mice to conclusively identify the neurotensin NTR1 receptor as the specific site through which CGX-1160 produces analgesia. A series of in vitro experiments
The patent covers RNA interference (RNAi) mediated inhibition of gene expression using short-interfering ribonucleic acids (siRNA), broadly covering any siRNA molecule which targets conserved sequences within a virus
“This phase IIa study in hepatitis C patients with celgosivir as monotherapy, along with the safety and nonclinical synergy data generated to date, supports our combination therapy development
The EMEA orphan drug designation provides incentives to companies that develop drugs for diseases affecting no more than 50 in 100,000 persons in the European Union, or drugs
Similar to development stage in-licensing deals, the terms of the agreement provide for success-based milestones per compound and royalties on the commercialization of drugs repositioned through Gene Logic’s